Company News-宜明昂科英文

2023-09-11

IMM2510 of ImmuneOnco completed Phase I dose escalation and determined recommended phase II dose

On September 11, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco", Hong Kong Stock Exchange stock code: 01541.HK) announced that IMM2510, a PD-L1/vEGF bispecific fusion protein independently developed by ImmuneOnco, completed Phase I dose escalation and determined the recommended Phase II dose.

2023-09-05

ImmuneOnco Listed on the Main Board of the HKEX

(Hong Kong, September 5th, 2023) ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (stock code: 01541.HK), today listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”).

2023-04-07

ImmuneOnco Biopharmaceuticals Named to KPMG China's "2nd Annual Biotechnology Innovation Top 50 Companies List"

On April 7, 2023, KPMG China's "2nd Biotechnology Innovation Top 50" award ceremony was held simultaneously in Beijing, Shanghai and Shenzhen, and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. was

2023-03-24

ImmuneOnco Biopharmaceuticals IMM47, IMM2520 and IMM2510 invention patents were granted by the State Intellectual Property Office of China

On March 24, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the patent applications for their independently developed products, IMM47 (CD2

2023-03-23

ImmuneOnco Biopharmaceuticals' IMM2520 project completes first subject dosing

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the phase I clinical trial of IMM2520, a bispecific antibody-receptor fusion protein that targets